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• Nerve growth factor is a well-characterized neuro- 
trophic protein required for the survival and differentiation 
of a variety ofneuronal cell types both in the peripheral and 
central nervous systems. Recent studies indicate that nerve 
growth factor also plays a role in cells originating in the im- 
mune system, since it is synthesized by cells of immune system 
lineage and its level increases during inflammatory responses. 
Moreover, it has been shown that cytokines such as interleukin- 
1J3 and tumor necrosis factor-a are potent inducers of nerve 
growth factor secretion. These studies were recently confirmed 
and extended by demonstrating that cells normally present in 
inflammatory tissues, such as mast cells and lymphocytes, 
express nerve growth factor receptors and are receptive to 
the action of nerve growth factor. The aim of the present re- 
view is to outline the current understanding of mast cells and 
nerve growth factor in autoimmune diseases and particularly 
in arthritis. 
INTRODUCTION 
• The term nerve growth factor (NGF) was introduced 
more than 40 years ago to define a newly discovered protein 
inducing neurite outgrowth from sensory and sympathetic 
ganglia in vivo and in vitro (1,2). NGF is synthesized and 
released in large amounts by the submaxillary salivary gland 
(SMG) of adult male mice(l-3). Lesser amounts have been 
found in snake venom (2), guinea pig prostate gland and semi- 
nal fluids of guinea pig and of bull (2,4), while nanogram 
quantities have been located in a variety ofneuronal and non- 
neuronal cells, both in the central and peripheral nervous sys- 
tems (2,5,6). The 2.5S NGF molecule isolated and purified 
from the SMG is a dimer of two identical subunits linked to- 
gether by non-covalent bonds and has a molecular weight of 
about 30 kD (7). The amino acid sequence and the primary 
structure of NGF from murine as well as from other species 
have been characterized and indicate highly conserved ho- 
mology of murine NGF with other species, including humans 
(2,6,8-10). 
The functional significance of NGF in the SMG and the physi- 
ological role of such a high concentration of NGF in these 
glands is largely unknown, although recent studies have shown 
that NGF released from the mouse SMG into the bloodstream 
following intraspecific aggressive behavior exerts an effect on 
at least two NGF target cells, the chromaffm cells and perito- 
neal mast cells (MC) (11-14). 
In recent years, mainly through the use of exogenous NGF 
and NGF-antibody administration, it has been shown that NGF 
has specific cell targets not only in the peripheral and central 
nervous system, but also in the endocrine and immune sys- 
tems. Accordingly, current knowledge indicates that NGF plays 
a functional role not only in neuropathological events associ- 
ated with learning, memory and aging but also in autoim- 
mune diseases, including rheumatoid arthritis (RA). 
NGF AMD THE PERIPHERAL NERVOUS SYSTEM 
• NGF functions as a retrograde trophic messenger be- 
tween target tissues and their innervating nerve cells. NGF 
and NGF mRNA have been detected in peripheral tissues of 
various mammalian species, whereas NGF receptor mRNA is 
mostly produced by the corresponding sensory and sympathetic 
ganglia (2,15,16). NGF exerts its neurotrophic activity in re- 
  
  
sponse to ligand-receptor binding followed by internalization 
and retrograde transport of the NGF-receptor complex to the 
neuronal cell body. Recent studies showed the presence of two 
different types of NGF receptors: p75 acting as a low-affinity 
receptor (Kd=10'
9
M) and pWO* high-affinity NGF receptor 
(Kd=10-"M) (17-19).  
Daily injection of purified NGF into neonatal rodents results 
in an increase in volume of sympathetic ganglia, hypertrophy 
of sensory ganglia, and in an augmentation of their neuro- 
transrnitiers within NGF target cells (2,15,20-22). The effect 
of NGF in sympathetic nerve cells is even more dramatically 
documented by the finding that removal of circulating NGF 
in living animals, via administration of specific NGF anti- 
bodies, results in death of sympathetic neurons, leading to what 
has been known for years as immunosympathectomy (23). 
NGF AMD THE CENTRAL NERVOUS SYSTEM 
• The actions of NGF are not limited to the peripheral 
nervous system. Numerous studies published in the last ten 
years have shown that NGF is produced in the central nervous 
system (5,6), that cholinergic basal forebrain neurons (CBFN) 
bear NGF receptors (17,19,24,25), and that these neurons are 
highly receptive to the action of NGF. NGF and its receptor 
are axonally transported retrogradely from cortex and hippoc- 
ampus to CBFN, where they exert a trophic action. It has also 
been clearly demonstrated that the degeneration of CBFN fol- 
lowing transection of the septo-hippocampal pathway is mark- 
edly reduced by exogenous administration of NGF. These stud- 
ies support the notion mat NGF exerts a functional effect on 
these brain neurons (26) not only during development but also 
in adult and aged life. Moreover, the widespread presence of 
NGF mRNA throughout cells of the central nervous system 
suggests other functions of this protein within the brain 
(13,14,27-30). 
NGF AMD THE ENDOCRINE SYSTEM 
• Apart from its well-known roles in the survival and 
development of peripheral sympathetic and sensory neurons 
and in CBFN, NGF is also known to take part in the regula- 
tion of specific neuroendocrine functions (13,30-34). In fact, 
it has been shown that both NGF and its mRNA increase in 
the hypothalamus following stressful events (11-14). More- 
over, the injection of NGF antibodies into rat fetuses results in 
a marked neuroendocrine deficit in postnatal life, including 
atrophied peripheral sympatetic and sensory ganglia (31). 
Deleterious effects of NGF deprivation during fetal life have 
also been reported in rats and guinea pigs (32,33). Further- 
more, maternal exposure to NGF antibodies causes, in new- 
born pups, loss of body weight, sensory deficits, and high 
mortality, probably associated to neuroendocrine and immune 
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alterations (30). In this context, it is worth mentioning that 
exogenous NGF administration acts on the hypothalamic-pi- 
tuitary-adrenal axis by influencing, most probably, the release 
of hypothalamic hormones (35). 
HGF AND THE IMMUNE SYSTEM 
• There is ample evidence that NGF is able to exert a 
wide variety of effects on cells of the immune system (36-47). 
These studies demonstrated that in vivo administration of NGF 
to neonatal rats causes a widespread increase in the size and 
number of MC in several peripheral tissues (36). Exposure of 
spleen cells to NGF antibodies results in a cytological alter- 
ation and a reduction of MC numbers. Recently, it has been 
shown that MC bear NGF receptors and that NGF induces 
degranulation and histamine release from isolated peritoneal 
MC (48-51). That NGF plays a role in the immune system is 
also suggested by findings which show that administration of 
NGF in young rats prior to and after immunization with sheep 
erythrocytes results in an enhancement of T-lymphocyte-de- 
pendent antibody synthesis (52). 
NGF has also been shown to be involved in inflammatory re- 
sponses. The observation that inflammation causes an increase 
in NGF levels was first reported by Levi-Montalcini and 
Angeletti, who showed that carrageenan-induced granuloma 
causes a dramatic local increase in NGF levels, far above that 
found with sarcoma 180 (53). These studies were recently con- 
firmed and extended, demonstrating mat cells normally present 
in inflammatory tissues, such as MC and lymphocytes, ex- 
press NGF receptors (46,50,54) and are receptive to the action 
of NGF (36,37). These findings along with the observation 
that NGF accumulates at the site of the lesion and inflamma- 
tion and that cytokines, such as interleukin-lB (IL-1|3) and 
tumor necrosis factor-a (TNF-a), are potent inducers of NGF 
secretion (55-57) suggest a functional link between cytokines 
and NGF in certain inflammatory diseases. 
HGF AMD AUTOIMMUNE DISEASES 
• The observation that the concentration of NGF is en- 
hanced in inflammatory response, along with the emerging 
evidence that cells of immune system lineage are able to re- 
spond to and/or synthesize NGF (30) led to the hypothesis 
that this molecule might be involved in autoimmune diseases. 
Thus, it was assumed that autoimmune diseases characterized 
by abnormal activation of the immune system and by alter- 
ation of numerous biologically active mediators may influ- 
ence the synthesis and release of NGF. Indeed, recent studies 
carried out in our laboratory demonstrated elevated NGF lev- 
els in a large number of autoimmune diseases (58-66). For 
example, NGF has been found in the synovial fluid of RA 
patients and other forms of chronic arthritis, as well as in the 
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synovium of animals with pharmacologically-induced arthri- 
tis (58-60). In the latter instance, destruction of peripheral 
sympathetic innervation reduced both the inflammation and 
the increased level of NGF caused by carrageenan injection 
(59). More recently, it was demonstrated that the synovium of 
transgenic arthritic mice carrying and expressing the human 
TNF-oc gene accumulates elevated levels of NGF. Interestingly, 
subcutaneous injection of NGF antibodies in these transgenic 
animals attenuated the wasting effect of TNF-oc (61). 
Basal levels of NGF were found to be altered in the presence 
of other autoimmune diseases. For example, the concentra- 
tion of NGF increases in the cerebrospinal fluid of patients 
with multiple sclerosis (MS) (62) and in the brain of rats af- 
fected by experimental allergic encephalomyelitis (EAE), an 
animal model of MS (63). A significant increase in NGF lev- 
els was observed in the sera of patients with systemic lupus 
erythematosus (SLE) and in dermis of patients affected by sys- 
temic sclerosis (SSc) (64,65). In most of these diseases, the 
increase of NGF was invariably associated with the accumu- 
lation of MC. In view of the fact that MC secrete NGF (67), 
express NGF mRNA and bear low- and high-affinity NGF 
receptors (50,54), and since both NGF and MC are up-regu- 
lated during inflammation, it is highly possible that either sin- 
gly or cooperatively they may be functionally involved in these 
diseases (68-75). 
MGF AMD MAST CELLS 
• Under normal conditions MC are found in diverse tis- 
sues and organs, including nervous tissue, skin, gastrointesti- 
nal and respiratory tracts, vascular wall and endocrine glands 
(68-70,76). MC have been identified in a variety of inflamma- 
tory states, such as SLE, mixed connective tissue disease, SSc, 
atopic dermatitis, MS, and EAE. They respond to and pro- 
duce a variety of cytokines, such as IL-1,3,4,5,6, TNF-oc, in- 
terferon-y, granulocyte-macrophage colony stimulating fac- 
tor and TNF-p (69,71). In addition, peptides derived from 
granulocytes, platelets, and mononuclear cells, as well as 
complement-derived peptides and certain proteases are able 
to stimulate MC secretion. MC can be activated by nervous 
and immunological mediators such as neuropeptides (e.g. sub- 
stance P) or immunoglobulin E (IgE) and are known to be 
involved in the development of immediate and delayed 
hypersensibility reactions (75,77-79). 
The observation that MC respond to NGF by increasing in 
numbers and by releasing biological mediators (30,48,67) and 
that they accumulate in the synovium of patients affected by 
arthritis and other inflammatory disorders (72-75), suggested 
that attention be focused on the role of NGF in autoimmune 
diseases. As a first approach to carry out this studies, we se- 
lected human and rodent arthritis. We therefore decided to 
study the relationship of MC and NGF in rodents and humans 
affected by this type of disease. Our data clearly indicate that 
human and experimentally-induced arthritis is characterized 
by an increase in MC numbers and that MC distribution is 
correlated to NGF levels (65,66). Since MC produce cytokines 
(69,71) and cytokines are known to influence the synthesis of 
NGF (55-57), the results of time-course studies will help to 
elucidate the functional relationship between NGF, MC and 
cytokines in autoimmune diseases. 
MGF. MAST CELLS AMD ARTHRITIS 
• RA is a multisystem, chronic, inflammatory disease of 
not well-defined origin (72-75). The inflammatory conditions 
are characterized by synovia! hypertrophy and hyperplasia, and 
mixed cell infiltration, including numerous MC (78-81). The 
observation that these cells are associated with development 
of an inflammatory infiltrate in arthritis suggested that the 
identification of the mechanism leading to the accumulation 
of MC might contribute to the development of better thera- 
peutic strategies for arthritis. 
The fact that MC are multifunctional cells which store and 
release numerous biological mediators, including histamine, 
heparin, cytokines (71) and NGF (67,81), raised the impor- 
tant question of what role NGF plays during the course of 
inflammatory diseases. Our previous studies showing that in- 
jection of NGF into neonatal rats causes an increase of MC 
led to the hypothesis that also in arthritis, the presence of MC 
is the result of an overproduction of NGF. During synovial 
inflammation the increase of NGF precedes the accumulation 
of MC. However, recent observations that injection of highly 
purified NGF into the knee joint does not induce inflamma- 
tion and that MC are able to release NGF (66,67) question 
this hypothesis and raise the possibility that MC may contrib- 
ute to up-regulation of synovial NGF. Based on the present 
findings, one possible explanation is that the presence of high 
NGF levels at the site of inflammation may serve as a regula- 
tory mechanism for a subpopulation of immunocompetent cells 
that are necessary for healing processes. The fact that MC can 
alter lymphocyte function favoring suppression of cytotoxic 
effects, whilst recruiting phagocytic leukocytes, supports this 
hypothesis (74). However, this hypothesis is consistent with 
the observations that IL-4 released by both MC/basophils and 
T-lymphocytes inhibits the production of proinflammatory 
cytokines such as IL-1, IL-6, IL-8 and TNF-oc (77). It is there- 
fore also possible that NGF acts through the action of IL-4 
which is also a potent inhibitor of synthesis by monocytes of 
both prostaglandin-E2 and collagenase. Indeed, IL-4 was able 
to reduce disease activities and progression in various arthritic 
models (77). 
Elevated concentrations of NGF have also been observed after   
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a number of degenerative events within and outside the ner- 
vous system and have been associated to neurite regeneration 
mechanisms (82-85). It is therefore possible that similarly to 
the nervous system, the increase of NGF and/or MC occur- 
ring in certain tissues during autoimmune diseases is linked 
to protective and reparative mechanisms (86-88). The obser- 
vation that the level of NGF in SSc, MS and in EAE is high 
during the acute phase and low during the remission one 
(62,63,66) is consistent with this hypothesis. Since NGF is 
known to act on cells of the nervous, immune and endocrine 
systems (30,76,85), it is possible that during inflammation its 
role is to participate in peripheral tissue repair and to reestab- 
lish physiological conditions. 
In this context is also worth mentioning that MC degranula- 
tion through release of heparin may also have antiinflammatory 
effects. For example, inhibition of T-lymphocyte heparanase 
by heparin has been shown to prevent T-cell migration, whereas 
treatment with low doses of heparin has been found to inhibit 
adoptively transferred encephalomyelitis (89,90). Heparin has 
also been demonstrated to modulate cell proliferation, wound 
healing, neurite outgrowth, and inflammation (91). Moreover, 
the potential role of peripheral MC may be related to connec- 
tive tissue formation in development or repair and in defence 
against parasite infection (84,85). 
CONCLUSIONS 
• Several autoimmune diseases, including arthritis, are 
associated with the release of numerous biologically active 
mediators from MC and since MC mediators are known to 
exert not only deleterious (69,72-74), but also beneficial ef- 
fects (84-93), a better understanding of the functional correla- 
tion between NGF and MC might be of great value for the 
development of therapeutic strategies for treating joint inflam- 
matory diseases. 
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